The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
Authors' conclusion
Our meta-analysis demonstrates that GLP-1 RAs exert significant anti-inflammatory effects in patients with T2DM. Our findings provide important insights that may guide the therapeutic application of GLP-1 RAs and inform the development of related therapies.
Study context
- Population
- Patients with T2D in randomised controlled trials (RCTs); median follow-up 24 weeks, mean age 54.13 years, 44.46% females, body mass index (BMI) 29.80 kg/m², HbA1c 8.28%, diabetes duration 7.27 years
- Participants
- 4,734 patients52 RCTs
- Comparison
- GLP-1 RA vs placebo or conventional diabetes therapies
- Outcome
- Changes in circulating inflammatory biomarkers (C-reactive protein (CRP), TNF-α, IL-6, IL-1β, leptin, adiponectin, PAI-1, MCP-1, AGEs)
Pooled result
As reported in the abstract
Circulating inflammatory markers (CRP, TNF-α, IL-6, IL-1β, leptin, adiponectin) · median follow-up 24 weeks
GLP-1 RA vs Placebo or conventional therapySMD (CI)
CRP; significant reduction
−0.63(−1.03 to −0.23)
TNF-α; significant reduction
−0.92(−1.57 to −0.27)
IL-6; significant reduction
−0.76(−1.32 to −0.20)
IL-1β; significant reduction
−3.89(−6.56 to −1.22)
Leptin; significant reduction
−0.67(−1.09 to −0.26)
Adiponectin; significant increase
0.69(0.19–1.19)
Original publication
The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →